B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $117 to $155.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.